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Objectives: To evaluate the effects of combined oral contraceptives (COC), containing 30 μg ethinyl estradiol (EE)/ 
3 mg drospirenone (DRSP) on metabolic and cardiovascular parameters in women with polycystic ovary syndrome.
Methods: Thirty patients diagnosed as PCOS according to Rotterdam criteria were included in this study. 30 μg 
EE/ 3 mg DRSP was taken for 6 months. Follicle stimulating hormone (FSH), leutinizing hormone (LH), LH/FSH 
ratio, E2, total cholesterol, low-density lipoprotein (LDL) cholesterol, high-density lipoprotein (HDL) cholesterol, 
triglyceride (TG), LDL/HDL ratio, atherogenic index of plasma (AIP), total testosterone, sex-hormone binding glob-
ulin (SHBG), free androgen index (FAI), 17 hydroxyprogesterone (17-OHP), dehydroepiandrosterone sulfate 
(DHEAS), fasting insulin, fasting glucose, homeostatis model assessment insulin resistance (HOMA-IR), homo-
cysteine, and high-sensitivity C-reactive protein (hsCRP) were measured at baseline and at the end of treatment.
Results: STherapy with 30 μg EE /3 mg DRSP significantly decreased LH/FSH ratio. The serum androgen levels 
including total testosterone, DHEAS, and 17 OHP decreased significantly and FAI was reduced significantly, ac-
companied by an increase of SHBG level. Total cholesterol, TG, LDL cholesterol, and HDL cholesterol increased 
significantly. The AIP and LDL/HDL ratio were not changed by COC treatment. HOMA IR, the glucose to insulin 
ratio and cardiovascular markers including hsCRP and homocysteine were not changed significantly.
Conclusion: Treatment with 30 μg EE/3 mg DRSP in women with PCOS, without significant negative impact on 
cardiovascular and metabolic parameters, COC with 30 μg EE/3 mg DRSP appears to be an effective drug in wom-
en with PCOS.
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Polycystic ovary syndrome (PCOS) is a common 
endocrine disorder of young women occurring globally 
in 6% to 10% of the population.1 Combined oral 
contraceptives (COC) are most frequently used for 
long-term management and are recommended as the 
primary treatment of menstrual irregularity. The 
components of COC, estrogens and progestogens, are 
known to have various metabolic effects, including 
effects on lipid metabolism and, on the risk for 
cardiovascular disease.2 Because of its possible 
deteriorating effect on carbohydrate metabolism and 
lipid profile, the use of COC in women with PCOS is 
still under scrutiny.3 However, the metabolic effects of 
COCs are extremely variable, depending on the dose 
of ethinyl estradiol (EE) and the type of progestin 
associated.4 A recently developed COC contains 30 μg 
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EE and 3 mg drospirenone (DRSP), a new progesto-
gen. This combination is known to have a high con-
traceptive efficacy in combination with an excellent 
cycle control and a low incidence of adverse effects.5-6 
Although there are few studies on effects of COC in 
women with PCOS, only a few trials have been done 
with drospirenone containing pills and more infor-
mations are needed to determine its metabolic and 
cardiovascular impacts. Therefore, this study was 
designed to evaluate the effects of COC, containing 
30 μg ethinyl estradiol (EE)/3 mg drospirenone (DRSP) 
on metabolic and cardiovascular parameters in women 
with PCOS.
MATERIALS AND METHODS
  Thirty patients diagnosed with PCOS who attended 
to the outpatient clinic of reproductive endocrinology of 
Yonsei University Health System between February 
2009 and February 2010 were enrolled in the study. 
The study protocol was approved by the ethics 
committee of Severance Hospital and Yonsei University 
College of Medicine, and Institutional Review Board 
approval was obtained. PCOS was defined according to 
the Rotterdam criteria.7 All subjects underwent trans-
vaginal or transrectal ultrasound in the follicular phase, 
on 3rd day of menstrual cycle. Subjects with hyperten-
sion, diabetes mellitus, personal history of cardio-
vascular events or received treatment with COCs, 
insulin sensitizers, or drugs that might interfere with 
lipid profile, cardiovascular marker, or carbohydrate 
metabolism for the previous 6 months were excluded. 
  All subjects were studied at baseline, during the 
follicular phase of the menstrual cycle, on 3rd day of 
menstrual cycle and after six cycles of treatment. The 
blood sampling was obtained at baseline and after 6 
months of treatment. Standing height and weight were 
measured and the mean BMI was calculated. Waist 
and hip circumferences were measured, and waist/hip 
ratio was also calculated. Blood samples were 
collected for fasting glucose, insulin, total cholesterol, 
low-density lipoprotein (LDL) cholesterol, high-density 
lipoprotein (HDL) cholesterol and triglyceride along 
with hormonal parameters including follicular stimula-
ting hormone (FSH), estradiol (E2), leutinizing hor-
mone (LH), total testosterone (T), sex-hormone bin-
ding globulin (SHBG), 17 hydroxyprogesterone (17- 
OHP) and dehydroepiandrosterone sulfate (DHEAS). 
The Free androgen index (FAI) was calculated: T 
(nmol/L) /SHBG (nmol/L) × 100. As for indicators of 
insulin sensitivity, the homeostasis model assessment 
of insulin resistance (HOMA-IR) was calculated using 
the following formula: (blood glucose × insulin)/22.5. 
The glucose/insulin ratio (G/I) was also calculated.4 
Homocysteine and high sensitivity C-reactive protein 
(hsCRP) was also obtained as cardiovascular markers. 
Atherogenic index plasma was calculated using the 
following formula: log (TG/HDL-C).
  After the baseline assessment, all patients were 
prescribed a monophasic COC containing 30 μg of EE 
plus 3 mg of DRSP (Yasmin; Schering AG, Berlin, 
Germany) for 6 months.
STATISTICAL ANALYSIS
  Analysis was done using the SPSS software 16.0 
(SPSS Inc, Chicago, IL, USA). Data are presented as 
mean±S.D. as appropriate. Paired t test was used to 
compare changes in follow-up values from baseline. A 
P value <0.05 was considered statistically significant. 
RESULTS
  Table 1 shows clinical and demographic charac-
teristics of the study population. Among the enrolled 
women, 16.6% had all three criteria of PCOS, 
irregular menstruation, hyperandrogenism and polycy-
stic ovary. The age of patients was 22.38±4.05 years.
  Effects of treatment on lipid profile are shown in 
Table 2. There were significant rises in total cholesterol 
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Table 1. Clinical characteristics in women with polycystic ovary syndrome
Baseline characteristic (n=30)
Age (years)
Parity (%)
  Nulliparous
  Multiparous
BMI (kg/m2)
Waist circumference (cm)
Waist/hip ratio
Phenotypes of PCOS (%)
  IM+HA+PCO
  IM+PCO
  HA+PCO
Menstrual pattern (%)
  Oligomenorrhea
  Amenorrhea
Modified FG scores
Ovarian volume (cm3)
  Right
  Left
22.38±4.05
 
93.3
 6.7
21.81±5.40
74.83±12.86
0.79±1.57
 
 16.7
50
 33.3
 
50
50
 9.70±5.30
 
10.38±5.38
 7.93±3.30
BMI, body mass index; HA, Hyperandrogenism; IM, Irregular 
Menstruation; PCO, polycystic ovary; FG scores, Ferriman- 
Gallwey scale. Values are the mean±SD.
Table 2. Biochemical parameters at baseline and after treatment 
Baseline (n=30) After treatment (n=30) P value
LH (mIU/mL)
FSH (mIU/mL)
LH/FSH ratio
E2 (pg/mL)
Total cholesterol (mg/dL)
LDL cholesterol (mg/dL)
HDL (mg/dL)
TG (mg/dL)
LDL/HDL ratio
AIP
Total testosterone (ng/dL)
SHBG (nmol/L)
FAI
DHEAS (mg/dL)
17-OH Progesterone (ng/mL)
Fasting glucose (mg/dL)
Fasting insulin (mg/dL)
Glucose/Insulin ratio
HOMA IR
hsCRP (mg/L)
Homocysteine (μmol/L)
 8.30±5.66
 5.38±1.50
 1.59±1.14
31.48±26.81
 171±26.39
97.67±27.98
57.77±14.27
82.00±32.61
 1.87±0.95
 0.13±0.24
53.84±25.09
45.66±21.97
 5.33±3.86
199.40±72.81
 1.29±0.86
85.87±5.77
 9.91±5.76
 1.16±6.31
 2.08±1.39
 1.88±3.23
12.13±3.20
 3.99±3.42
 5.75±2.70
 0.81±0.67
22.60±15.83
202.41±31.88
112.09±31.11
71.13±15.21
114.07±50.52
 1.67±0.62
 0.18±0.25
37.78±19.07
171.55±44.21
 1.00±1.21
160.86±68.82
 0.76±0.36
84.28±6.12
 8.81±4.17
 1.21±6.61
 1.85±0.92
 1.04±0.78
12.26±2.39
<0.001
0.422
<0.001
0.096
<0.001
0.001
<0.001
0.001
0.055
0.271
0.001
<0.001
<0.001
0.026
0.006
0.221
0.540
0.909
0.600
0.252
0.634
AIP, atherogenic index of plasma; DHEAS, dehydroepiandrosterone sulfate; FAI, free androgen index; FSH, follicle stimulating 
hormone; HDL; high-density lipoprotein; HOMA IR, homeostatic model assessment insulin resistance; LDL, low-density 
lipoprotein; LH, leutinizing hormone; TG, triglyceride; SHBG, sex hormone-binding globulin; 17-OHP, 17 hydroxyrogesterone. 
Values are the mean±SD.
(171.00±26.39 vs. 202.41±3 1.88, P<0.001), trigly-
ceride (82.00±32.61 vs. 114.07±50.52, P=0.001), LDL 
cholesterol (97.67±27.98 vs. 112.09±31.11, P=0.001), 
and HDL cholesterol (57.77±14.27 vs. 71.13±15.21, 
P<0.001) from baseline and at the end of 6 months of 
treatment.
  There was no change in glycemic profile at the end 
of 6 months treatment. None of the patients were 
found to be diabetic either at baseline or at the end of 
treatment.
  As compared to the baseline, hormonal profile 
showed significant decrease after 6 months of treat-
ment. LH (8.30±5.66 vs. 3.99±3.42, P<0.001), LH/ 
FSH ratio (1.59±1.14 vs. 0.81±0.67, P<0.001), Total 
testosterone (53.84±25.09 vs. 37.78±19.07, P=0.001), 
17-OHP (1.29±0.86 vs. 0.76±0.36, P=0.006), and DHEAS 
(199.40±72.81 vs. 160.86±68.82, P=0.026) were signifi-
cantly decreased at the end of treatment, accompanied 
by an increase of SHBG levels (45.66±21.97 vs. 
171.55±44.21, P<0.001). As a consequence the FAI 
(5.33±3.86 vs. 1.00±1.21, P<0.001) was significantly 
reduced. Indexes of cardiovascular risk did not differ 
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before and after the treatment.
DISSCUSSION
  After 6 months of therapy, there was a significant 
improvement in the hormonal profile with falls in the 
level of total testosterone, LH, LH/FSH ratio, and 
DHEAS level and a rise in SHBG concentration. 
  DRSP is a unique progestin derived from 17 α
-spironolactone; it shares progesterone’s antiandro-
genic and anti-mineralcorticoid properties, with no 
androgenic, estrogenic, glucocorticoid or antigluco-
corticoid activity.8-10 Although clinical manifestations 
of hyperandrogenism were not assessed in our study, 
Guido et al11 reported improvement in F-G score and 
hirsutism, along with androgenic profiles. Similar 
results were found by Ibanez et al.12 These results 
reflect the antiandrogenic activity of DRSP. 
  Several studies have reported that augmented LH 
pulse amplitude and increased expression of LH 
receptors in the ovaries of women with PCOS are 
considered to be central in the pathogenesis of the 
syndrome.15-16 Therefore, decrease in LH would be 
beneficial in the treatment of PCOS. With this respect, 
similar to previous studies,11,13 significant decrease in 
LH levels and LH/FSH ratio were observed in our 
study. With this finding, we could speculate a strong 
antigonadotropic activity of DRSP. 
  One of the issues concerning the use of COCs in 
women with PCOS is the increase of the insulin 
resistance and the induction of glucose intolerance, 
thereby affecting the carbohydrate metabolism. Con-
flicting data exist regarding this issue. According to 
Palep-Singh et al14, EE/DRSP combined OC impairs 
insulin resistance as do other COCs, while Guido et 
al.11 reported no deterioration in glucose tolerance. No 
significant impairment of carbohydrate metabolism 
occurred in our study. 
  Controversial data have been reported on the 
changes in the lipid profile with EE/DRSP thera-
py.6,8,11-12 Triglycerides and HDL cholesterol levels 
were significantly increased in most studies with 
significant decrease in LDL.11-13 As a result of in-
crease in HDL cholesterol and a LDL cholesterol 
level, the HDL/LDL ratio increase after EE/DRSP 
treatment, which is considered beneficial with respect 
to cardiovascular disease risk reduction.17 A significant 
increase in HDL cholesterol, Triglycerides, total 
cholesterol level and LDL cholesterol level was 
observed in our study, but with no shift in the HDL: 
LDL ratio. In this respect, the changes in the lipid 
profile with EE/DRSP therapy do not seem to have a 
negative impact on cardiovascular risk. 
  It is well known that PCOS patients have higher 
risk of cardiovascular events than normal healthy 
people. Among the surrogate markers of cardiova-
scular disease, homocysteine is an intermediate pro-
duct formed by the breakdown of methionine18 and 
hyperhomocysteinemia was shown to be a risk factor 
for atherogenesis and chronic vascular damage, es-
pecially when insulin levels increased.19 After 6 
months of therapy with EE/DRSP, no subjects showed 
an increase of homocysteine level, which is in 
agreement with Merki-Feld et al.20 Highly sensitive 
C-reactive protein (hsCRP) is a chronic subclinical 
inflammation marker which is known as an another 
predictive marker of cardiovascular events. Its eleva-
tion in PCOS patients have been reported in many 
studies.21-22 In this study, there was no significant 
change in hsCRP level after 6 months of therapy with 
EE/DRSP and this could be reflected by the report of 
Mohlig et al. that serum CRP levels are associated 
with obesity rather than with the presence of PCOS 
per se.23 
  In conclusion, a six months of treatment with 30 μ
g of EE plus 3 mg of DRSP is efficacious in women 
with PCOS patients to improve hyperandrogenic 
hormonal profile, without negative impact both on 
metabolic and cardiovascular parameters. However, 
our results were obtained with a small sample size 
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and should be reconsidered with a large population 
and more long-term follow-up period to further assess 
the metabolic and cardiovascular parameters of PCOS 
and the relationship to COCs.
REFERENCES
 1. Azziz R, Woods KS, Reyna R, Key TJ, Knochenhauer 
ES, Yildiz BO. The prevalence and features of the 
polycystic ovary syndrome in an unselected population. 
J Clin Endocrinol Metab 2004; 89: 2745-9.
 2. The European Agency for the Evaluation of Medi-
cinal Products (EMEA). Committee for proprietary 
medicinal products (CPMP). Note for guidance on 
clinical investigation of steroid contraceptives in 
women. 17 February 2000 CPMP/EWP/519/98.
 3. Nader S, Diamanti-Kandarakis E. Polycystic ovary 
syndrome, oral contraceptives and metabolic issues: a 
new perspectives and a unifying hypothesis. Hum 
Reprod 2007; 22: 317-22.
 4. Franca F, Daria P, Veronica L, Donatella P, Marco 
G, Andrea R. Comparison of effects of 3 mg dro-
spirenone plus 20 g ethinyl estradiol alone or com-
bined with metformin or cyproterone acetate on 
classic metabolic cardiovascular risk factors in 
nonobese women with polycystic ovary syndrome. 
Fertil Steril 2010; 94: 1793-8.
 5. Huber J, Foidart JM, Wuttke W, Bouw GM, Gerlinger 
C, Hithecker R. Efficacy and tolerability of a monophasic 
oral contraceptive containing ethinylestradiol and dro-
spirenone. Eur J Contracept Reprod Health Care 2005; 
5: 25-34. 
 6. Parsey KS, Pong A. An open-label, multi-centered 
study to evaluate Yasmin, a low-dose combination 
oral contraceptive containing drospirenone, a new 
progestogen. Contraception 2000; 61: 105-11.
 7. The Rotterdam ESHRE/ASRM Sponsored PCOS 
Consensus Workshop. Revised 2003 consensus on 
diagnostic criteria and long-term health risks related 
to polycystic ovary syndrome (PCOS). Fertil Steril 
2004; 81: 19-26.
 8. Oelkers W. Antimineralocorticoid activity of a novel 
oral contraceptive containing drospirenone, a unique 
progestogen resembling natural progesterone. Eur J 
Contracept Reprod Health Care 2002; 7(Suppl 3): 
19-26.
 9. Apter D, Borsos A, Baumgartner W. Effect of an 
oral contraceptive containing drospirenone and 
ethinylestradiol on general well-being and fluid- 
related symptoms. Eur J Contracept Reprod Health 
Care 2003; 8: 37-51.
10. Mansour D. Experiences with Yasmin: the accepta-
bility of a novel oral contraceptive and its effect on 
well-being. Eur J Contracept Reprod Health Care 
2002; 7(Suppl 3): 35-41.
11. Guido M, Roumualdi D, Giuliani M. Drospirenone 
for the treatment of hirsute women with polycystic 
ovary syndrome: a clinical, endocrinological, meta-
bolic pilot study. J Clin Endocrinol Metab 2004; 89: 
2817-23.
12. Ibanez L, de Zegher F. Ethinylestradiol-drospirenone, 
flutamide-metformin, or both for adolescents and 
women with hyperinsulinemic hyperandrogenism: 
opposite effects on adipocytokines and body adi-
posity. J Clin Metab 2004; 89: 1592-7.
13. Muhn P, Krattenmacher R, Beier S, Elger W, 
Schillinger E. Drospirenone: a novel progestogen 
with antimineralocorticoid and antiandrogenic acti-
vity: pharmacological characterization in animal 
models. Contraception 1995; 51: 99-110.
14. Palep-Singh M, Mook K, Barth J. An observational 
study of Yasmin in the management of women with 
polycystic ovary syndrome. J Fam Plann Reprod 
Health Care 2004; 30: 163-5.
15. McCartney CR, Eagleson CA, Marshall JC. Regula-
tion of gonadotropin secretion: implications for poly-
cystic ovary syndrome. Semin Reprod Med 2002; 20: 
317-26.
16. Adashi EY, Resnick CE, D’Ercole J, Svoboda ME, 
Van Wyk JJ. Insulinlike growth factor as intraovarian 
Kyung Jin Lim, et al：The Effect of Combined Oral Contraceptives on Metabolic and Cardiovascular Parameters in Patients with Polycystic Ovary Syndrome
115
regulators of granulosa cell growth and function. 
Endocr Rev 1985; 6: 400-20.
17. Kriplani A, Periyasamy AJ, Agarwa Nl, Kulshrestha 
V, Kumar A, Ammini AC. Effect of oral con-
traceptive containing ethinyl estrdiol combined with 
drospirenone vs. desogestrel on clinical and bioche-
mical parameters in patients with polycystic ovary 
syndrome. Contraception 2010; 82: 139-46.
18. Welch GN, Lo Scalzo J: Homocysteine and athero-
thrombosis. N Engl J Med 1998; 338: 1042-50.
19. House JD, Stead LM, Brosnan ME, Brosnan JT. 
Regulation of homocysteine metabolism. Adv Enzyme 
Regul 1999; 39: 69-91.
20. Merki-Feld GS, Imthurn B, Keller PJ. Effects of two 
oral contraceptives on plasma levels of nitric oxide, 
homocysteine, and lipid metabolism. Metabolism 2005; 
51:1216-21.
21. Diamanti-Kandarakis E, Paterakis T, Alexandraki K, 
Piperi C, aessopos A, Katisikis. Indices of low-grade 
chronic inflammation in polycystic ovary syndrome 
and the beneficial effect of metformin. Hum Reprod 
2006; 21(6): 1426-31.
22. Orio F, Jr Palomba S, Cascella T, Di Biase S, 
Manguso F, Tauchmanova L. The increase of leuko-
cytes as a new putative marker of low-grade chronic 
inflammation and early cardiovascular risk in poly-
cystic ovary syndrome. J Clin Endocrinol metab 
2005; 90(1): 2-5.
23. Mohlig M, Spranger J, Osterhoff M. The polycystic 
ovary syndrome per se is not associated with in-
creased chronic inflammation. Eur J Endocrinol 
2004; 150: 525-32.
Journal of Reproductive Endocrinology Vol. 2, No. 2
116
❙ 국문초록 ❙
연구목적:  30 μg estradiol (EE)ր3 mg drospirenone (DRSP)ଡ෌କ෉෻෍լ֜඿ହઊଲ
ٖۗনٍীஹบ֞ฅୀଭ۩ॷୡࢫਕ෯ւծ஺ඝ઩ࢠ౿ۀઽේ઩۩෇઱ंজ෇઼ .ۗ
연구대상 및 방법: Rotterdam ஼ۚ׆ஜ઩෍ۥ෉ୢ఼ٖۗনٍীஹบ֞ฅୀ30ࡣଡ۩
ঃଞߦ30 μg EE/3 mg DRSP լ ֜඿ହઊଡ6Թଁԩ࣫૳෇઼ .ۗ ෹࠙ࡩՑॷ, ౑಻ߑਆ
ൈߩ, ୠࢤܑ஺ۚࢽ(LDL), ճࢤܑ஺ۚࢽ(HDL), ணন஺ࢺ(TG), LDL/HDL णࢫ౑ഓਆ
ഠਆഓߨ, ন෹࠙ࡩէ෍ ۚࢽ(SHBG), 17 hydroxyprogesterone (17-OHP), dehydroepian-
drosterone sulfate (DHEAS)ࠜ౸୨෇઱Free androgen index (FAI) ࠜծॺ෇઼ .ۗ վ࣫଴ਂ
ࠦࢫ෯ۥଡ౸୨෇ճhomeostatic model assessment of insulin resistance (HOMA-IR)ࠜծ
ॺ෇઼ଞ࡝, ஺ா Ցॷ, atherogenic index of plasma (AIP) ࢫ ෹ࡦਏਆഓ଴ր high- 
sensitivity C-reactvie protein (hs-CRP)ࠜઊ࣫૳ୢր6Թଁܶ઩Ցॷ෇઼ .ۗ 
결과: 30 μg EE/3 mg DRSP լ֜඿ହઊଞߦ౿߹෉էրLH/FSH णԧକଭ෇՚Ԯী෇
઼ଞ࡝, ౑ഓਆഠਆഓߨ, DHEAS, ֻࠤճ17-OHP ࠜඑ෌෉෯఻ੲ݁ߦ՛৤౿݅ଲକଭ
෇՚Ԯী෇઼ .ۗ ށFAIԧଭࢠ଼՚ٗੰ୷ճSHBGԧஹԧ෇઼ .ۗ ౑಻ߑਆൈߩ, ணন
஺ࢺ, LDL, ֻࠤճHDLଲକଭ෇՚ஹԧ෉ࢱ࡟, AIP૕LDL/HDL णۀ࣡ฃԧઢત .ۗ 
HOMA-IRր /ۥ଴ਂࠦणࢫhs CRP૕homocysteineࠜඑ෌෉ਕ෯ւծ஺ඝ઩ۀକଭ෉
ఙଲԧઢત .ۗ
결론: ٖۗনٍীஹบ֞ฅୀ઩ছ30 μg EE/3 mg DRSP լ֜඿ହઊ౿߹ۀ۩ॷࢫਕ෯
ւծ஺ඝ઩ऀ୨ୡ଴ઽේଡࢠ౿஺ੴੰٖۗনٍীஹบ֞ฅୀ઩՚ॷ૳෌઩଼ઘੲ
ୢ්Փଞߦॷ߹ܤ .ۗ
 
중심단어: ݁ߦਆ඿ߑڍ, լ֜඿ହઊ, ٖۗনٍীஹบ֞
